Skip to content

cancer

For a company of our size, we are aiming in oncology to become:

Renowned

among health care
professionals and
patients for our commitment

Focused

on rare cancers,
technology
and action drivers

Innovative

by creating open ecosystems, investing heavily in R&D and developing precision medicine

A three-pronged approach to our oncology strategy

  1. Target hard-to-treat cancers
    Guided by patient needs, we strive to develop major therapeutic innovations in areas where needs are greatest. We wish to initiate therapeutic progress where generally speaking needs are not yet met, known as hard-to-treat cancers, such as digestive cancers (stomach cancer, pancreatic cancer, and cholangiocarcinoma, a rare and aggressive form of bile duct cancer), glioma, or brain tumors, hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma) and pediatric cancers.
  2. Concentrate on promising and complementary therapeutic approaches
    Servier concentrates its R&D programs in oncology in two promising areas:
    • Immuno-oncology, to activate the immune system against cancer cells ;
    • Targeted therapies, to specifically target one of the biological mechanisms of cancer cells.
  3. Draw on a wide range of expertise
    Our teams boast a high level of expertise, which is why we encourage cross-divisional collaboration through our various research centers throughout the world. All our R&D centers work in a collaborative manner, pooling their remarkable expertise through cutting-edge technology platforms:
    • Our R&D center in Boston is located in the heart of one of the world’s most innovative health ecosystems ;
    • Symphogen in Denmark is our high quality monoclonal and bi-specific antibody center of excellence ;
    • Our future Servier R&D Institute at Paris-Saclay, which will open its doors in 2023

To step up the pace of research and development in innovative treatments, we unrelentingly promote and pursue open innovation with pharmaceutical labs, biotech companies, prestigious academic institutions and start-ups.

In oncology, we have formed around 40 research partnerships and collaborations.

Focus

7 oncology treatments available for patients throughout the world

Learn more about our oncology development projects

For patients

Improving patients’ quality of life

We have published a number of brochures developed in collaboration with expert patients, patient representatives, carers and health care professionals. Written for patients living with digestive cancers to support them, as well as their family, throughout their cancer journey, these brochures form part of SHAPE,2 an international program launched by Servier in collaboration with Digestive Cancers Europe.

For patients

Cover of the MyDialogue brochure for health professionals
Cover of the MyFood patient brochure
Cover of the MyMood patient brochure

Leukemia

Photo of a child with leukemia in the hospital

Everything there is to know about acute lymphoblastic leukemia

This cancer, that involves the bone marrow, affects a particular type of white blood cells, lymphoblasts (lymphocytes at an early stage of development). It is the most common leukemia in children, although it affects all age groups.

Understanding acute myeloid leukemia

Acute myeloid leukemia (AML) is a rare disease which mainly affects the elderly. It is a blood and bone marrow cancer which develops rapidly without therapeutic treatment.

Photo of a leukemia patient in the hospital

Got a question?

Want to report a side effect?
Check out our Pharmacovigilance page.

[1] World Health Organization

[2] “Support Harmonized Advances for better Patient Experiences”